FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Article

AVNR, PWRM, ENER, BIOS - Market Updates From DrStockPick.com!

Posted, by drstockpick on November 3rd, 2010

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of Power3, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."

"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

***************************************************

BioScrip Inc. (Nasdaq:BIOS) announced that Richard “Rick” M. Smith, currently President and Chief Operating Officer, has been named Chief Executive Officer, effective January 1, 2011. Mr. Smith will replace Richard H. Friedman, currently Chairman of the Board and Chief Executive Officer (CEO), who will be stepping down as CEO to serve as Non-Executive Chairman of the BioScrip Board of Directors, effective January 1, 2011.

BioScrip, Inc., a specialty pharmaceutical healthcare organization, provides medications and management solutions for chronic and other healthcare conditions in the United States. It operates through two segments, Specialty Pharmacy Services and Traditional Pharmacy Services.

***************************************************

Energy Conversion Devices, Inc. (Nasdaq:ENER) the leading global provider of thin-film flexible solar laminate products and systems for the building integrated and commercial rooftop markets, will report financial results for the first quarter of fiscal year 2011 ended September 30, 2010 before the market opens on Tuesday, November 9, 2010. In conjunction with the release, ECD’s management will host a conference call at 10:00 a.m. EST on Tuesday, November 9, 2010 to review the financial results. To participate in the conference call, please dial (877) 858-2512 or (706) 643-3219 (international) at least 10 minutes prior to the start of the call. Callers will need to reference conference ID number 18689375. The conference call will be webcast live over the Internet and can be accessed in the Investor Relations section of the company’s website under “Events".

Energy Conversion Devices, Inc. engages in the design, manufacture, and sale of photovoltaic (PV) products. The company operates in two segments, United Solar Ovonic and Ovonic Materials. The United Solar Ovonic segment provides PV laminates that generate clean and renewable energy by converting sunlight into electricity.

***************************************************

Avanir Pharmaceuticals (Nasdaq:AVNR) announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect. NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient’s underlying emotional state.

AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada.

***************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).

READ MORE AT: 
Authored by, drstockpick
Log in or register to post Private Message
Advertise with us

Add new comment

By submitting this form, you accept the Mollom privacy policy.